A prospective, multicenter biobank cohort study in the UK and US revealed that very high high-density lipoprotein cholesterol (HDL-C) levels were associated with higher mortality risk in patients with coronary artery disease (CAD). There were 14 478 UK participants (from 2006; mean age 62.1 years, 76.2% men) and 5467 US participants (from 2003; mean age 63.8 years, 66.4% men). Over a median follow-up of 8.9 years in the UK and 6.7 years in the US, a U-shaped association with outcomes was observed with higher risk in those with both low and very high HDL-C levels compared with those with midrange values. Very high HDL-C levels (>80 mg/dL) were associated with increased risk of all-cause death (hazard ratio [HR], 1.96) and cardiovascular death (HR, 1.71) compared with those with HDL-C levels in the range of 40 to 60 mg/dL in the UK after adjustment for confounding factors. These results were replicated in the US. These associations persisted after adjustment for the HDL-C genetic risk score within the UK cohort. Sensitivity analyses demonstrated that the risk of all-cause mortality in the very high HDL-C group was higher among men than women in the UK (HR, 2.63 vs HR, 1.39). The findings suggest that although previous studies have shown lower cardiovascular risk with higher HDL-C levels, very high HDL-C levels are paradoxically associated with higher mortality risk in patients with CAD, independent of the common polymorphisms associated with high HDL-C levels. Source: https://jamanetwork.com/
A study revealed that stroke remains a major global health challenge, influenced by numerous risk…
A systematic review and meta-analysis evaluated randomized controlled trials on pharmacological treatments for anxiety in…
A global study suggested that most patients with coronary heart disease (CHD) have Lipoprotein (a)…
A recent article explored the science and skepticism surrounding seed oils. These oils—extracted from sources…
A Canadian study of adults with high blood pressure (BP) found no difference in health…
Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester…
This website uses cookies.